Business CircleBusiness Circle
  • Home
  • AI News
  • Startups
  • Markets
  • Finances
  • Technology
  • More
    • Human Resource
    • Marketing & Sales
    • SMEs
    • Lifestyle
    • Trading & Stock Market
What's Hot

Imperial Petroleum (IMPP) Q4 Earnings Surge 250% YoY to $0.35 EPS on Strong Tanker Utilization

March 7, 2026

PB Fintech: Goldman Sachs, Tata Mutual Fund buy stake in Rs 695 crore block deal

March 7, 2026

As RTO surges, childcare benefits demand rises

March 7, 2026
Facebook Twitter Instagram
Saturday, March 7
  • Advertise with us
  • Submit Articles
  • About us
  • Contact us
Business CircleBusiness Circle
  • Home
  • AI News
  • Startups
  • Markets
  • Finances
  • Technology
  • More
    • Human Resource
    • Marketing & Sales
    • SMEs
    • Lifestyle
    • Trading & Stock Market
Subscribe
Business CircleBusiness Circle
Home » CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating (NASDAQ:CTIC)
Finances

CTI BioPharma Corp.: Pacritinib Approval, Downgrade To A Sell Rating (NASDAQ:CTIC)

Business Circle TeamBy Business Circle TeamApril 11, 2022No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


This text was written by

BiotechValley Insights profile picture

We concentrate on small and mid-cap healthcare and expertise firms. We publish quick and lengthy concepts.Disclaimer: Biotechvalley Insights (BTVI) shouldn’t be a registered funding advisor, and articles should not focused towards retail traders. BTVI explicitly denies that his opinions are knowledgeable in any method. The reader is inspired to assessment publicly out there info and carry out different analysis earlier than figuring out whether or not they agree with the opinions of the writer. The content material is for informational functions solely, you shouldn’t construe any such info or different materials as authorized, tax, funding, monetary, or different recommendation. Nothing contained in our articles or feedback constitutes a solicitation, suggestion, endorsement, or supply by Biotechvalley Insights or any third get together service supplier to purchase or promote any securities or different monetary devices on this or in every other jurisdiction through which such solicitation or supply could be illegal beneath the securities legal guidelines of such jurisdiction. Biotechvalley insights group (“I”) doesn’t obtain direct compensation from the businesses that we cowl or talked about in our articles apart from SeekingAlpha, however the info supplied by Biotechvalley insights could also be biased and/or embody conflicts of curiosity/competing pursuits as some members of the group might maintain related lengthy/quick positions and/or have an affiliation/enterprise relationship with the businesses which might be talked about within the articles.

Disclosure: I/we now have no inventory, choice or related spinoff place in any of the businesses talked about, however might provoke a useful Brief place by means of short-selling of the inventory, or buy of put choices or related derivatives in CTIC over the subsequent 72 hours. I wrote this text myself, and it expresses my very own opinions. I’m not receiving compensation for it (apart from from In search of Alpha). I’ve no enterprise relationship with any firm whose inventory is talked about on this article.

Further disclosure: Biotechvalley Insights (BTVI) shouldn’t be a registered funding advisor, and articles should not focused towards retail traders. The content material is for informational functions solely, you shouldn’t construe any such info or different materials as authorized, tax, funding, monetary, or different recommendation. Nothing contained in our articles or feedback constitutes a solicitation, suggestion, endorsement, or supply by Biotechvalley Insights or any third get together service supplier to purchase or promote any securities or different monetary devices on this or in every other jurisdiction through which such solicitation or supply could be illegal beneath the securities legal guidelines of such jurisdiction.

The analysis and studies made out there by BTVI mirror specific the opinion of the relevant BTVI Entity as of the time of the report solely. Studies are primarily based on generally-available info, area analysis, inferences, and deductions by means of the relevant due diligence and analytical course of. BTVI might use sources from brokerage studies, company IR, and KOL/knowledgeable interviews which will have a battle of curiosity to the corporate/belongings that BTVI covers. To the perfect of the relevant BTVI’s capacity and perception, all info contained herein is correct and dependable, shouldn’t be materials private info, and has been obtained from public sources that the relevant BTVI Entity believes to be correct and dependable. Nonetheless, such info is offered “as is,” with out guarantee of any form, whether or not specific or implied. With respect to their respective analysis studies, BTVI makes no illustration, specific or implied, as to the accuracy, timeliness, or completeness of any such info or with regard to the outcomes to be obtained from its use. Additional, any evaluation/remark incorporates a really massive measure of research and opinion. All expressions of opinion are topic to alter with out discover, and BTVI doesn’t undertake to replace or complement any studies or any of the knowledge, evaluation, and opinion contained in them.



Source link

approval BioPharma Corp CTI Downgrade NASDAQCTIC Pacritinib rating Sell
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Business Circle Team
Business Circle Team
  • Website

Related Posts

PB Fintech: Goldman Sachs, Tata Mutual Fund buy stake in Rs 695 crore block deal

March 7, 2026

What Netflix’s acquisition of Ben Affleck’s AI filmmaking company really shows

March 6, 2026

Best Debt Settlement Companies of 2026: Compare Fees and Savings

March 6, 2026

30 Healthy Dinners Under $1.50 That Don’t Taste Cheap

March 6, 2026
LATEST UPDATES

Imperial Petroleum (IMPP) Q4 Earnings Surge 250% YoY to $0.35 EPS on Strong Tanker Utilization

March 7, 2026

PB Fintech: Goldman Sachs, Tata Mutual Fund buy stake in Rs 695 crore block deal

March 7, 2026

As RTO surges, childcare benefits demand rises

March 7, 2026

Subscriber Search Is Now Up To 12x Faster

March 7, 2026

15 Legal Mistakes First-Time Founders Should Avoid

March 7, 2026

What Netflix’s acquisition of Ben Affleck’s AI filmmaking company really shows

March 6, 2026

Subscribe to Updates

Get the latest sports news from SportsSite about soccer, football and tennis.

Business, Finance and Market Growth News Site

Important Pages
  • Advertise with us
  • Submit Articles
  • About us
  • Contact us
Recent Posts
  • Imperial Petroleum (IMPP) Q4 Earnings Surge 250% YoY to $0.35 EPS on Strong Tanker Utilization
  • PB Fintech: Goldman Sachs, Tata Mutual Fund buy stake in Rs 695 crore block deal
  • As RTO surges, childcare benefits demand rises
© 2026 BusinessCircle.co
  • Privacy Policy
  • Terms and Conditions
  • Cookie Privacy Policy
  • Disclaimer
  • DMCA

Type above and press Enter to search. Press Esc to cancel.